EBC-46

EBC-46
Clinical data
injected
Identifiers
 Yes
PubChem CID 23627739
Chemical data
Formula C30H42O10
562.647
 Yes (what is this?)  (verify)

EBC-46 is a experimental drug candidate being studied pre-clinically[1] by the Australian company Ecobiotics (specifically its drug discovery subsidiary Qbiotics). It was discovered through an automated screening process of natural products by selecting increasingly purified fractions of plant extracts, based on their ability to produce the desired activity profile. This is then followed by artificial synthesis of the isolated compound to confirm its chemical structure. EBC-46 is a phorbol ester which, along with other related compounds, acts as a protein kinase C regulator.[2]

The initial lead came from observation that marsupials found the seed of Fontainea picrosperma unpalatable due to an inflammatory chemical present in reasonably high concentrations. This was identified as 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tiglian-3-one.[3]

See also

References

  1. ↑ Boyle, G. M.; d'Souza, M. M. A.; Pierce, C. J.; Adams, R. A.; Cantor, A. S.; Johns, J. P.; Maslovskaya, L.; Gordon, V. A.; Reddell, P. W.; Parsons, P. G. (2014). "Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models". PLoS ONE 9 (10): e108887. doi:10.1371/journal.pone.0108887.
  2. ↑ Aitken, A. (1987). "The activation of protein kinase G by daphnane, ingenane and tigliane diterpenoid esters". Botanical Journal of the Linnean Society 94: 247. doi:10.1111/j.1095-8339.1987.tb01049.x.
  3. ↑ Tiglian-3-one derivatives. Patent WO 2007/070985